NEW YORK (GenomeWeb News) – Sequenom President and CEO Harry Stylli said yesterday that the firm would work with a contract sales force organization and is targeting a sales force of 150 to 175 reps focused on the obstetrics/gynecology market in the US for its SEQureDx Down Syndrome test that it intends to launch in June.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.